USANA’s 350% EPS Surge: Why the Stock Lags

Forward-Looking Analysis

Wall Street analysts project significant earnings growth for Usana Health Sciences in 2026, with consensus estimates forecasting total earnings of $39.9 million, ranging from a low of $38.4 million to a high of $41.1 million. This implies an average Earnings Per Share (EPS) of $2.16, representing a substantial 350.5% increase from previous periods. For 2027, earnings are expected to rise further to $52.2 million, with an EPS forecast of $2.83. Revenue is anticipated to grow moderately, with 2026 estimates at $17.8 billion and 2027 at $18.9 billion, reflecting a 4.11% annual growth rate that outpaces the Packaged Foods industry average of 1.55% but lags the broader US market. Analysts forecast a Return on Assets (ROA) of 7.06%, exceeding the industry average of 5.68%, though Return on Equity (ROE) is projected at a weaker 9.6%. While the stock trades near its 52-week low, these aggressive EPS growth projections suggest potential upside if the company executes its strategic principles effectively.

Historical Performance Review

In Q1 2026, Usana reported net sales of $250.22 million and net income of $6.96 million. The company achieved a gross profit of $190.78 million, resulting in a diluted EPS of $0.41. These figures indicate a recovery in profitability compared to the prior year's declines, with net income increasing 523.38% sequentially. The strong gross margin demonstrates effective cost management, positioning the company for potential continued improvement in upcoming quarters as it implements its customer attraction and product innovation strategies.

Additional News

Recent corporate developments highlight USANA's focus on product quality and strategic partnerships. On July 30, 2026, the company released a 12-week consumer study validating visible skin benefits for USANA Glow. Earlier, on July 20, 2026, USANA renewed a four-year partnership with Nordiq Canada, reinforcing its commitment to clean sport and elite athlete nutrition. Product innovation remains a key driver, with Celavive Contouring Face & Neck Crème recognized among Canada's top skincare products in June 2026. Additionally, USANA earned dual Best of State honors for product innovation and development. The company also celebrated its People-First Culture by appearing on the USA TODAY Top Workplaces List in May 2026. These initiatives underscore management's emphasis on research, development, and brand engagement to support long-term growth.

Summary & Outlook

Usana Health Sciences demonstrates improving financial health, evidenced by a sharp sequential rebound in Q1 2026 net income and EPS. Growth catalysts include strong analyst forecasts for exceptional EPS growth (350.5% annually) and robust ROA, supported by product innovation and international expansion strategies. However, revenue growth remains modest compared to the broader market, and low ROE forecasts present a risk. Despite trading near 52-week lows, the company's solid cash position and strategic focus on high-quality products suggest a neutral to cautiously bullish outlook, contingent on successfully executing customer acquisition initiatives and sustaining the momentum from recent product validations.